Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Chaperones as Suppressors of Protein Misfolded Oligomer Toxicity.

Mannini B, Chiti F.

Front Mol Neurosci. 2017 Apr 5;10:98. doi: 10.3389/fnmol.2017.00098. eCollection 2017. Review.

2.

The amyloid interactome: Exploring protein aggregation.

Biza KV, Nastou KC, Tsiolaki PL, Mastrokalou CV, Hamodrakas SJ, Iconomidou VA.

PLoS One. 2017 Mar 1;12(3):e0173163. doi: 10.1371/journal.pone.0173163. eCollection 2017.

3.

Nucleobindin 1 binds to multiple types of pre-fibrillar amyloid and inhibits fibrillization.

Bonito-Oliva A, Barbash S, Sakmar TP, Graham WV.

Sci Rep. 2017 Feb 21;7:42880. doi: 10.1038/srep42880.

4.

Clearance of cerebral Aβ in Alzheimer's disease: reassessing the role of microglia and monocytes.

Zuroff L, Daley D, Black KL, Koronyo-Hamaoui M.

Cell Mol Life Sci. 2017 Jun;74(12):2167-2201. doi: 10.1007/s00018-017-2463-7. Epub 2017 Feb 14. Review.

5.

Clusterin: full-length protein and one of its chains show opposing effects on cellular lipid accumulation.

Matukumalli SR, Tangirala R, Rao CM.

Sci Rep. 2017 Jan 25;7:41235. doi: 10.1038/srep41235.

6.
7.

Plasma clusterin levels and risk of dementia, Alzheimer's disease, and stroke.

Weinstein G, Beiser AS, Preis SR, Courchesne P, Chouraki V, Levy D, Seshadri S.

Alzheimers Dement (Amst). 2016 Jul 9;3:103-9. doi: 10.1016/j.dadm.2016.06.005. eCollection 2016.

8.

Multifaceted anti-amyloidogenic and pro-amyloidogenic effects of C-reactive protein and serum amyloid P component in vitro.

Ozawa D, Nomura R, Mangione PP, Hasegawa K, Okoshi T, Porcari R, Bellotti V, Naiki H.

Sci Rep. 2016 Jul 6;6:29077. doi: 10.1038/srep29077.

9.

Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging.

Gupta VB, Doecke JD, Hone E, Pedrini S, Laws SM, Thambisetty M, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Macaulay SL, Rembach A, Rainey-Smith SR, Martins RN; AIBL Research Group.

Alzheimers Dement (Amst). 2015 Dec 22;3:18-26. doi: 10.1016/j.dadm.2015.12.001. eCollection 2016.

10.

Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer's disease cohorts.

Tan L, Wang HF, Tan MS, Tan CC, Zhu XC, Miao D, Yu WJ, Jiang T, Tan L, Yu JT; Alzheimer’s Disease Neuroimaging Initiative.

Sci Rep. 2016 May 27;6:26027. doi: 10.1038/srep26027.

11.

Clusterin Binds to Aβ1-42 Oligomers with High Affinity and Interferes with Peptide Aggregation by Inhibiting Primary and Secondary Nucleation.

Beeg M, Stravalaci M, Romeo M, Carrá AD, Cagnotto A, Rossi A, Diomede L, Salmona M, Gobbi M.

J Biol Chem. 2016 Mar 25;291(13):6958-66. doi: 10.1074/jbc.M115.689539. Epub 2016 Feb 16.

12.

Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology.

Baird AL, Westwood S, Lovestone S.

Front Neurol. 2015 Nov 16;6:236. doi: 10.3389/fneur.2015.00236. eCollection 2015. Review.

13.

Interaction between variants in CLU and MS4A4E modulates Alzheimer's disease risk.

Ebbert MT, Boehme KL, Wadsworth ME, Staley LA; Alzheimer's Disease Neuroimaging Initiative; Alzheimer's Disease Genetics Consortium, Mukherjee S, Crane PK, Ridge PG, Kauwe JS.

Alzheimers Dement. 2016 Feb;12(2):121-9. doi: 10.1016/j.jalz.2015.08.163. Epub 2015 Oct 9.

14.

Specific chaperones and regulatory domains in control of amyloid formation.

Landreh M, Rising A, Presto J, Jörnvall H, Johansson J.

J Biol Chem. 2015 Oct 30;290(44):26430-6. doi: 10.1074/jbc.R115.653097. Epub 2015 Sep 9. Review.

15.

Transthyretin Amyloidosis: Chaperone Concentration Changes and Increased Proteolysis in the Pathway to Disease.

da Costa G, Ribeiro-Silva C, Ribeiro R, Gilberto S, Gomes RA, Ferreira A, Mateus É, Barroso E, Coelho AV, Freire AP, Cordeiro C.

PLoS One. 2015 Jul 6;10(7):e0125392. doi: 10.1371/journal.pone.0125392. eCollection 2015.

16.

SerpinB2 (PAI-2) Modulates Proteostasis via Binding Misfolded Proteins and Promotion of Cytoprotective Inclusion Formation.

Lee JA, Yerbury JJ, Farrawell N, Shearer RF, Constantinescu P, Hatters DM, Schroder WA, Suhrbier A, Wilson MR, Saunders DN, Ranson M.

PLoS One. 2015 Jun 17;10(6):e0130136. doi: 10.1371/journal.pone.0130136. eCollection 2015.

17.

Regulating extracellular proteostasis capacity through the unfolded protein response.

Genereux JC, Wiseman RL.

Prion. 2015;9(1):10-21. doi: 10.1080/19336896.2015.1011887.

18.

Amyloid β Protein and Alzheimer's Disease: When Computer Simulations Complement Experimental Studies.

Nasica-Labouze J, Nguyen PH, Sterpone F, Berthoumieu O, Buchete NV, Coté S, De Simone A, Doig AJ, Faller P, Garcia A, Laio A, Li MS, Melchionna S, Mousseau N, Mu Y, Paravastu A, Pasquali S, Rosenman DJ, Strodel B, Tarus B, Viles JH, Zhang T, Wang C, Derreumaux P.

Chem Rev. 2015 May 13;115(9):3518-63. doi: 10.1021/cr500638n. Epub 2015 Mar 19. Review. No abstract available.

19.

Systemic amyloidosis: lessons from β2-microglobulin.

Stoppini M, Bellotti V.

J Biol Chem. 2015 Apr 17;290(16):9951-8. doi: 10.1074/jbc.R115.639799. Epub 2015 Mar 6. Review.

20.

Cooperative stabilization of transthyretin by clusterin and diflunisal.

Greene MJ, Klimtchuk ES, Seldin DC, Berk JL, Connors LH.

Biochemistry. 2015 Jan 20;54(2):268-78. doi: 10.1021/bi5011249. Epub 2014 Dec 24.

Supplemental Content

Support Center